Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
Would you give adjuvant chemotherapy for adenoid cystic carcinoma of breast that is low ER positive, early stage, node negative?
Would you use oncotype to guide your decision?
Answer from: Medical Oncologist at Academic Institution
Simple answer: No.
Sign in or Register to read more
3431
Related Questions
What factors do you take into account when deciding which gene expression assay to utilize when making adjuvant treatment decisions in patients with non-metastatic breast cancer?
What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
How would you treat a T2N1 ER 90%, PR 10%, HER-2 negative breast cancer in premenopausal women with a tumor abutting the pectoralis fascia with loss of fat plane, with a concern for a positive surgical margin?
How do you reconcile data from the PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic ER+ HER2+ breast cancer?
In what situations would you consider doublet chemotherapy in treatment of a premenopausal de novo metastatic TNBC?
How do the findings from the INAVO120 trial influence your decision-making process for selecting subsequent lines of therapy in patients who have relapsed after adjuvant CDK4/6 inhibition?
What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?
How would you manage an isolated nodal recurrence of breast cancer in a patient with a prior history of mantle-field radiation?